Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities |
| 10/2/2024 | $400.00 → $250.00 | Outperform → Market Perform | Leerink Partners |
Reports 4Q24 net loss per share of $5.76 on a GAAP basis, Adjusted net loss per share of $2.16; reports FY 2024 earnings per share (EPS) of $9.98 on a GAAP basis, $16.21 on an Adjusted basis 4Q24 Insurance segment Adjusted benefit ratio of 91.9 percent, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations Affirms previous commentary of Adjusted FY 2025 EPS guidance to be 'at least in line with 2024 results'; anticipating GAAP EPS of approximately $15.88, or approximately $16.25 on an Adjusted basis, inclusive of incremental investments to support operational excellence Expects individual Medicare Advantage annua
Humana Inc. (NYSE:HUM) will release its financial results for the fourth quarter 2024 (4Q24), as well as prepared management remarks (in PDF format), on Tuesday, February 11, 2025, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BIe3b4c275f3cf421383fa6ac8a142593b. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique re
AM Best has downgraded the Financial Strength Rating (FSR) to B+ (Good) from B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) to "bbb-" (Good) from "bbb" (Good) of Humana Insurance of Puerto Rico, Inc. and Humana Health Plans of Puerto Rico, Inc. These companies are domiciled in Puerto Rico and collectively are referred to as Humana Health of Puerto Rico Group. The outlook of these Credit Ratings (ratings) has been revised to negative from stable. Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICRs of "a" (Excellent) for the health and dental insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) (NYSE:HUM). These sub
3 - HUMANA INC (0000049071) (Issuer)
3 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare Advantage members in Alabama, Louisiana, Mississippi, Tennessee, and now Georgia with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) will have access to Monogram's evidence-based nephrology and multispecialty value-based care in the comfort of their homes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213062933/en/ Value-based care focuses on the collaboration and coordination of all aspects of a patient's care, and th
Reports 4Q24 net loss per share of $5.76 on a GAAP basis, Adjusted net loss per share of $2.16; reports FY 2024 earnings per share (EPS) of $9.98 on a GAAP basis, $16.21 on an Adjusted basis 4Q24 Insurance segment Adjusted benefit ratio of 91.9 percent, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations Affirms previous commentary of Adjusted FY 2025 EPS guidance to be 'at least in line with 2024 results'; anticipating GAAP EPS of approximately $15.88, or approximately $16.25 on an Adjusted basis, inclusive of incremental investments to support operational excellence Expects individual Medicare Advantage annua
Over a decade of Humana's research shows value-based care improves patient outcomes Value-based care results in patients spending more time with their primary care clinician, less time in the hospital, and more frequent preventive care, based on research released today by leading health and well-being company Humana Inc. (NYSE:HUM) in its annual Value-Based Care Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250205385393/en/Over a decade of Humana's research shows value-based care improves patient outcomes. (Photo: Humana) The report's data shows that Medicare Advantage (MA) patients receiving care under value-based ar
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
Bernstein upgraded Humana from Mkt Perform to Outperform and set a new price target of $308.00
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
8-K - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
10-Q - HUMANA INC (0000049071) (Filer)
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
4 - HUMANA INC (0000049071) (Issuer)